| Assessment Status | Rapid Review Complete |
| HTA ID | 24008 |
| Drug | Ublituximab |
| Brand | Briumvi® |
| Indication | For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. |
| Assessment Process | |
| Rapid review commissioned | 28/02/2024 |
| Rapid review completed | 02/04/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ublituximab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations. September 2024
